Ms Hogan, from Edinburgh, says she agrees with Health Secretary Wes Streeting that the drug could potentially help people ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

Rapid weight loss from the glucagon-like peptide 1 (GLP-1s) can reduce fat tissue in face that makes for a smooth, more ...

WeightWatchers (WW International) (NASDAQ:WW) stock is trading higher on Wednesday, with a session volume strong at 31.45 ...

The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

As the obesity clinical trials evolve, there is a growing emphasis on how decentralisation and new technologies can play a ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide ... You should pull it down to the same volume as your prescribed dose. Puncture the top of the medication ...

better known under the trade names Ozempic and Wegovy, is remarkable, but it's not totally unprecedented in the history of pharmaceutical blockbusters. The volume of prescriptions and the budget ...

Novo Nordisk said that the launch of Wegovy had “unlocked” the obesity ... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can ...

As signs emerge that demand for GLP-1 drugs is stronger than expected, many are fearing the worst for packaged-food companies, but Bernstein believes that some companies are likely to fare better than ...